UCB's Global Corporate Website
Welcome to UCB in the United States
  • Healthcare Professionals
  • Patients
  • Investors
  • Feb

    05

    The Lancet Publishes Two Phase 3 Studies Detailing Bimekizumab Data in Moderate to Severe Plaque Psoriasis

    Oct

    31

    Bimekizumab Phase 3 Data Shows Superior Skin Clearance Over Humira® in Moderate-to-Severe Psoriasis Patients

    Aug

    11

    The Impact of Psoriasis: Infographic

    At UCB, we are committed to supporting the psoriasis community and working to improve the future for those living with the disease. In honor of Psoriasis Awareness Month, we’re shining a spotlight on the over 7 million people in the U.S. impacted by psoriasis every day.

    Jun

    11

    Empowering Patients Impacted by Immuno-Dermatological Conditions

    At UCB, everything we do starts with one simple question: “How will this make a difference in the lives of people living with severe diseases?” This question is our motivation, inspiration and what challenges us to stay focused on what will ultimately benefit the patients we serve. Read more from Camille Lee, Head of U.S. Immunology, about how UCB is working to empower patients impacted by immuno-dermatological conditions.